PCI has facilitated nearly twenty major multi-year alliances with corporate partners and startup companies that have helped to further accelerate the commercialization of Penn ideas into products that provide therapies and cures for patients, as well as supporting a broad range of sustained R&D activities at Penn. For example, Penn’s multiple large-scale alliances in the area of cell and gene therapy have dramatically accelerated the growth of what is increasingly globally referenced as ‘Cellicon Valley’ centered around Penn and based in Greater Philadelphia. Two of Penn’s alliance partners had successful IPOs this past year: Cabaletta Bio and Passage Bio and corporate alliances continue to be a vital driver of PCI and Penn’s commercialization and product development activities.
